<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> FR89303-0064 </DOCNO><DOCID>fr.3-03-89.f2.A1063</DOCID><TEXT><ITAG tagnum="94"><ITAG tagnum="69"><ITAG tagnum="50">DEPARTMENT OF HEALTH AND HUMAN SERVICES</ITAG><ITAG tagnum="18">Food and Drug Administration</ITAG><ITAG tagnum="41">[Docket No. 88M-0447]</ITAG><ITAG tagnum="52">CIBA Vision Corp.; Premarket Approval of CIBA Vision Sterile SalineSolution and CIBA Vision Sterile Buffered Saline Solution</ITAG><ITAG tagnum="10"><T2>AGENCY: </T2>Food and Drug Administration.</ITAG><ITAG tagnum="10"><T2>ACTION: </T2>Notice.</ITAG><ITAG tagnum="10"><T2>SUMMARY: </T2>The Food and Drug Administration (FDA) is announcingits approval of the application by CIBA Vision Corp., Atlanta, GA, forpremarket approval, under the Medical Device Amendments of 1976, of theCIBA Vision Saline Solution and CIBA Vision Sterile Buffered Saline Solution.The devices are to be manufactured under an agreement with Armstrong Laboratories,Inc., West Roxbury, MA, which has authorized CIBA Vision Corp. to incorporateinformation contained in its approved premarket approval applications forthe Armstrong Sterile Saline Solution and the Armstrong Sterile BufferedSaline Solution. FDA's Center for Devices and Radiological Health (CDRH)notified the applicant, by letter of December 23, 1988, of the approvalof the application.</ITAG><ITAG tagnum="10"><T2>DATE: </T2>Petitions for administrative review by April 3, 1989.</ITAG><ITAG tagnum="10"><T2>ADDRESS: </T2>Written requests for copies of the summary of safetyand effectiveness data and petitions for administrative review to the DocketsManagement Branch (HFA-305), Food and Drug Administration, Rm. 4-62, 5600Fishers Lane, Rockville, MD 20857.</ITAG><ITAG tagnum="10"><T2>FOR FURTHER INFORMATION CONTACT:</T2>David M. Whipple, Center for Devicesand Radiological Health (HFZ-460), Food and Drug Administration, 8757 GeorgiaAve., Silver Spring, MD 20910, 301-427-7940.</ITAG><ITAG tagnum="10"><T2>SUPPLEMENTARY INFORMATION: </T2>On October 27, 1988, CIBA Vision Corp.,Atlanta, GA 30360, submitted to CDRH an application for premarket approvalof the CIBA Vision Sterile Saline Solution and the CIBA Vision SterileBuffered Saline Solution. The devices are sterile physiological salinesolutions (0.9 percent salt in water) in pressurized containers with anitrogen propellant and are indicated for use in the rinsing, heat disinfection,and storage of soft (hydrophilic) contact lenses. The application includesauthorization from Armstrong Laboratories, Inc., West Roxbury, MA 02132,to incorporate information contained in its approved premarket approvalapplications for the Armstrong Sterile Saline Solution and the ArmstrongSterile Buffered Saline Solution.On December 23, 1988, CDRH approved the application by a letter to theapplicant from the Acting Director of the Office of Device Evaluation,CDRH.A summary of the safety and effectiveness data on which CDRH based itsapproval is on file in the Dockets Management Branch (address above) andis available from that office upon written request. Requests should beidentified with the name of the device and the docket number found in bracketsin the heading of this document.A copy of all approved labeling is available for public inspection at CDRH_contactDavid M. Whipple (HFZ-460), address above.<ITAG tagnum="84">Opportunity for Administrative Review</ITAG>Section 515(d)(3) of the Federal Food, Drug, and Cosmetic Act (the act)(21 U.S.C. 360e(d)(3)) authorizes any interested person to petition, undersection 515(g) of the act (21 U.S.C. 360e(g)), for administrative reviewof CDRH's decision to approve this application. A petitioner may requesteither a formal hearing under Part 12 (21 CFR Part 12) of FDA's administrativepractices and procedures regulations or a review of the application andCDRH's action by an independent advisory committee of experts. A petitionis to be in the form of a petition for reconsideration under andSection;10.33(b) (21 CFR 10.33(b)). A petitioner shall identify the form of reviewrequested (hearing or independent advisory committee) and shall submitwith the petition supporting data and information showing that there isa genuine and substantial issue of material fact for resolution throughadministrative review. After reviewing the petition, FDA will decide whetherto grant or deny the petition and will publish a notice of its decisionin the <T4>Federal Register</T4>. If FDA grants the petition, the notice willstate the issue to be reviewed, the form of review to be used, the personswho may participate in the review, the time and place where the reviewwill occur, and other details.Petitioners may, at any time on or before April 3, 1989, file with theDockets Management Branch (address above) two copies of each petition andsupporting data and information, identified with the name of the deviceand the docket number found in brackets in the heading of this document.Received petitions may be seen in the office above between 9 a.m. and 4p.m., Monday through Friday.This notice is issued under the Federal Food, Drug, and Cosmetic Act (secs.515(d), 520(h), 90 Stat. 554-555, 571 (21 U.S.C. 360e(d), 360j(h))) andunder authority delegated to the Commissioner of Food and Drugs (21 CFR5.10) and redelegated to the Director, Center for Devices and RadiologicalHealth (21 CFR 5.53).<ITAG tagnum="21">Dated: February 22, 1989.</ITAG><ITAG tagnum="6">Walter E. Gundaker,</ITAG><ITAG tagnum="4">Acting Deputy Director Center for Devices and Radiological Health.</ITAG><ITAG tagnum="40">[FR Doc. 89-4957 Filed 3-2-89; 8:45 am]</ITAG><ITAG tagnum="68">BILLING CODE 4160-01-M</ITAG></ITAG></ITAG></ITAG></TEXT></DOC>